Pfizer Inc. (NYSE:PFE) Shares Acquired by Denali Advisors LLC

Denali Advisors LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 11.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,200 shares of the biopharmaceutical company’s stock after buying an additional 3,100 shares during the period. Denali Advisors LLC’s holdings in Pfizer were worth $810,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Carret Asset Management LLC increased its position in shares of Pfizer by 10.4% in the first quarter. Carret Asset Management LLC now owns 122,917 shares of the biopharmaceutical company’s stock valued at $3,411,000 after buying an additional 11,577 shares in the last quarter. Tradewinds Capital Management LLC increased its position in shares of Pfizer by 27.3% in the first quarter. Tradewinds Capital Management LLC now owns 2,330 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 500 shares in the last quarter. Plimoth Trust Co. LLC increased its position in shares of Pfizer by 2.2% in the first quarter. Plimoth Trust Co. LLC now owns 64,723 shares of the biopharmaceutical company’s stock valued at $1,796,000 after buying an additional 1,406 shares in the last quarter. Silverlake Wealth Management LLC increased its position in shares of Pfizer by 11.0% in the first quarter. Silverlake Wealth Management LLC now owns 52,848 shares of the biopharmaceutical company’s stock valued at $1,467,000 after buying an additional 5,223 shares in the last quarter. Finally, Naviter Wealth LLC increased its position in shares of Pfizer by 80.9% in the first quarter. Naviter Wealth LLC now owns 38,987 shares of the biopharmaceutical company’s stock valued at $1,082,000 after buying an additional 17,430 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PFE. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, June 26th. Morgan Stanley lifted their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $35.54.

Pfizer Stock Performance

Shares of PFE stock opened at $27.67 on Thursday. The company’s fifty day simple moving average is $27.96 and its 200-day simple moving average is $27.71. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The company has a market cap of $156.79 billion, a PE ratio of -461.09, a P/E/G ratio of 1.09 and a beta of 0.69.

Pfizer (NYSE:PFE) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the firm posted $1.23 EPS. The business’s revenue for the quarter was down 19.5% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.07%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.